https://www.kaziatherapeutics.com/site/PDF/9640d28a-0022-4d6…
United States Food
and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to Kazia’s
paxalisib for the treatment of atypical rhabdoid / teratoid tumors (AT/RT), a rare and highlyaggressive childhood brain cancer.
Up significantly in pre-market trading.
IP